Editas Medicine, Inc. (NASDAQ:EDIT) trading at $25.71 after decline. It was reported on Apr, 17 according to Barchart.com. It has $1.26 billion MC. The company’s valuation will be $75.30M less at $24.17 price target.

On May, 2. Investors expect Editas Medicine, Inc. (NASDAQ:EDIT) to announce its quarterly earnings, Zacks reports. Analysts have anticipation on stock’s earnings per share of $-0.68. That’s down 1.49 % from last year’s $-0.67 earnings per share. Wall Street now sees 30.77 % negative EPS growth despite Editas Medicine, Inc. previous quarter’s EPS of $-0.52.

For more Editas Medicine, Inc. (NASDAQ:EDIT) news published recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Fool.com. The titles are as follows: “Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon – Nasdaq” published on April 11, 2019, “EDIT Crosses Above Key Moving Average Level – Nasdaq” on April 08, 2019, “Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons to Consider – Nasdaq” with a publish date: March 21, 2019, “Why Editas Medicine Stock Popped 18.5% in March – Nasdaq” and the last “How Editas Medicine Could Make You Better (and Richer) – The Motley Fool” with publication date: April 09, 2019.

Editas Medicine, Inc. operates as a genome editing company.The firm is worth $1.26 billion. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes.Last it reported negative earnings. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.